Kasuni Gayathri Ileperuma

Kasuni Gayathri Ileperuma

Auto-generated profile, based on publicly available information

Kasuni Gayathri Ileperuma

Chulalongkorn University

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2026 in Records of Natural Products
Verified
Journal Article
Closed access
KIKasuni Gayathri Ileperuma
Kasuni Gayathri Ileperuma
TCThawanrat Chirapiriyakul
Thawanrat Chirapiriyakul
Fozia RustamaniFozia Rustamani
Fozia Rustamani
NNNonthaneth Nalinratana
Nonthaneth Nalinratana
Normal 0 false false false false EN-US X-NONE TH /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-parent:""; mso-padding-alt:0cm 5.4pt 0cm 5.4pt; mso-para-margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-ansi-language:EN;} Normal 0 false false false false EN-US X-NONE TH /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-parent:""; mso-padding-alt:0cm 5.4pt 0cm 5.4pt; mso-para-margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-ansi-language:EN;} Triple-negative breast cancer (TNBC) lacks targeted therapies, creating a need for selective antiproliferative agents. We evaluated pongamol, a flavonoid from the roots of Millettia erythrocalyx Gagnep., against MDA-MB-231 TNBC cells, using the non-tumorigenic line MCF-10A as a normal-cell control. Pongamol preferentially reduced MDA-MB-231 viability (54.95 ± 7.08% versus 83.10 ± 6.34% at 200 µM after 24 h). After 72 h the IC50 was 65.83 ± 4.65 µM in MDA-MB-231 cells but approximately 200 µM in MCF-10A cells, giving a selectivity index of about 3. Network pharmacology identified 83 shared targets, with CDK1 among the protein–protein interaction hubs and Gene Ontology enrichment dominated by regulation of the G2/M transition. Pongamol inhibited proliferation (to 47% at 50 µM) and colony formation (to 31% of control at 25 µM), and induced G2/M arrest at 5 µM with a progressive increase in the sub-G1 population. In a cell-free assay, pongamol inhibited CDK1/cyclin B1 kinase activity (IC50 = 22.15 ± 4.23 µM), and docking predicted that it occupies the CDK1 ATP-binding site. These findings identify pongamol as a preferentially active, CDK1-inhibiting lead compound in the MDA-MB-231 model of TNBC, warranting validation in additional TNBC cell lines.